Azurity Pharmaceuticals
Azurity Pharmaceuticals is seeking a dynamic leader to manage the R&D Project Management department and drive process improvement initiatives at its Hyderabad development center. This role involves overseeing cross-functional planning, budgeting, and tracking of project plans while ensuring alignment with portfolio and product lifecycle management goals. The position requires leading digital enablement efforts, managing vendor relationships, and collaborating with senior leadership to streamline pharmaceutical R&D workflows.
Headquarters
Woburn, Massachusetts, United States
Company Size
501-1000 employees
Founded
2000
Azurity Pharmaceuticals is a privately held specialty pharmaceutical company committed to delivering innovative, high-quality medicines for overlooked patients. The company offers a diversified portfolio of 50+ branded medicines spanning 10 dosage forms and 10 key therapeutic areas, with a global footprint in over 50 countries. Azurity leverages a Next-Gen Commercial Model powered by data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement.
Formulation specialist Azurity to lay off 75 amid plans to sunset Massachusetts plant
Jul 14, 2025
Mass. drugmaker to close manufacturing facility, lay off 75 workers
Jul 11, 2025
QHP Capital runs single-asset CV process for pharma company – updated
Jun 6, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Azurity Pharmaceuticals.
Azurity Pharmaceuticals didn’t post a salary, so this is our estimate from similar listings.
25% above the average for this role
PATENT—Fed. Cir.: Alkem’s vancomycin oral solution did not infringe Azurity’s liquid antibiotic formulation patent
Apr 8, 2025